The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

AstraZeneca (NASDAQ:AZN) announced Thursday that gefurulimab, its experimental injectable for generalized myasthenia gravis, ...

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...

The chief executive of Muscular Dystrophy UK and interim chief executive of Myaware UK have shared thoughts on the rejection by the NHS in England of two potential myasthenia gravis treatments.

Myasthenia gravis (MG) ... Disease in these patients may progress further before healthcare advice is sought, leading to delays in treatment escalation, Strober and colleagues said.

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

Nicholas J. Silvestri, MD, describes how this year’s AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics through cell-based assays that enhance ...

The Food and Drug Administration (FDA) has approved Imaavy ™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older ...

"Almost all drugs used in myasthenia gravis are immunologics, such as prednisolone, azathioprine etc. But tirasemtiv is a symptomatic therapy could improve strength in patients who don't respond ...